Bioptigen raises $1.5M for optical imaging system
Bioptigen Inc., a company that has developed in vivo optical imaging systems that enables real-time, noninvasive imaging of internal tissue microstructure, has closed its first securities offering in four years raising $1.5 million from a single investor, according to a regulatory filing.
Bioptigen is a spin-out of the Duke University Biomedical Engineering Department. Bioptigen was incorporated in North Carolina in August, 2004, to commercialize technologies originating in the laboratories of Professor Joseph Izatt.
The company’s technology is based on the science of Optical Coherence Tomography, an imaging system similar in function to ultrasound, but using low-power light rather than sound waves.
OCT offers resolution 100-times finer than standard ultrasound, suitable for analyzing tissue microstructure with features smaller than 4 micrometer.
Principals named in the current Reg D filign are Bioptigen President CEO Eric Buckland and CFO Thomas Livingston. Bioptigen sold $542,500 in mixed securities in 2007.
The company disclosed the current raise in a filing with the US Securities and Exchange Commission. The filing can be seen HERE.